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Peste des Petits Ruminants Virus (PPRV) is an extremely infective morbillivirus that 
primarily affects goats and sheep. In underdeveloped countries where livestock are the 
main economical resource, PPRV causes considerable economic losses. Protective live 
attenuated vaccines are currently available but they induce antibody responses similar to 
those produced in PPRV naturally infected animals. Effective vaccines able to distinguish 
between vaccinated and naturally infected animals are required to PPRV control and 
eradication programs. Hemagglutinin (H) is a highly immunogenic PPRV envelope glyco-
protein displaying both hemagglutinin and neuraminidase activities, playing a crucial role 
in virus attachment and penetration. In this study, a recombinant Bovine Herpesvirus-4 
(BoHV-4)-based vector delivering an optimized PPRV-Hemagglutinin expression cas-
sette, BoHV-4-A-PPRV-H-ΔTK, was assessed in immunocompetent C57BL/6 mice. 
BoHV-4-A-PPRV-H-ΔTK-immunization elicited both cellular and humoral immune 
responses with specific T cell, cytotoxic T  lymphocyte, and sero-neutralizing antibody 
against PPRV. These data suggest recombinant BoHV-4-A-PPRV-H-ΔTK as an effective 
vaccine candidate to protect against PPRV herd infection and potentially applicable for 
eradication programs.
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inTrODUcTiOn
Peste des Petits Ruminants (PPR) is an often fatal, highly contagious, and devastating disease affect-
ing domestic small ruminants and especially goats. PPR is an Office International des Epizooties 
(OIE)-listed disease (http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2018/), 
endemic in several countries such as India, Turkey, Africa, and Southwest and Central Asia. Mouth 
Abbreviations: BoHV-4, bovine herpesvirus 4; BAC, bacterial artificial chromosome; BEK, bovine embryo kidney; HEK293T, 
human embryo kidney 293 T; VDS, vero dog-SLAM; FBS, fetal bovine serum; EMEM, eagle’s minimal essential medium; 
DMEM, dulbecco’s modified essential medium; DMSO, dimethyl sulfoxide; MOI, multiplicity of infection; TCID50, tissue 
culture infectious doses 50; EDTA, ethylenedinitrilo-tetraacetic; PEI, polyethylenimine; CPE, cytopathic effect; MFI, mean 
fluorescence intensity; PPR, peste des petits ruminants; PPRV, peste des petits ruminants virus; PPRV-H, peste des petits rumi-
nants virus hemagglutinin; H, hemagglutinin; DIVA, differentiating infected from vaccinated animals; OIE, office international 
des epizooties.
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and tongue lesions, cough, diarrhea, nasal and ocular discharge, 
and depression are typical clinical PPR disease signs. The PPR 
disease etiological agent is Peste des Petits Ruminants Virus 
(PPRV), a single-stranded negative sense enveloped RNA virus 
belonging to Paramixoviridae family, Morbillivirus genus (1) 
whose genome contains six genes coding for eight proteins. 
Among these, Hemagglutinin (H) is a structural glycoprotein 
with hemagglutinin and neuraminidase activities, involved 
in host cell targeting and virus attachment. H glycoprotein is 
an immunodominant antigen which, alone, can stimulate a 
protective immune-response when delivered by several viral 
vectors, mainly based on adenovirus (2–4) and poxvirus (5, 6). 
These antigen immune-properties would allow the generation 
of a Differentiating Infected from Vaccinated Animals (DIVA) 
vaccine. Since PPRV H glycoprotein is the only PPRV antigen 
expressed by the viral vector, the use of an ELISA against a dif-
ferent antigen, such as PPRV nucleo-capsid protein (N), would 
allow to distinguish naturally infected animals from vaccinated 
animals. Viral vectors are not only simply delivery systems but 
they can also work as adjuvants, unspecificaly stimulating the 
immune system and therefore increasing the specific active/
protective immunity. Different classes of viruses have been tested 
as viral vectors and each presents particular advantages and 
disadvantages, depending on their biological characteristics and 
on the host, who needs to be protected toward a specific disease. 
Hence, it is arduous to predict which viral vector could be the 
best. A specific viral-vector should be able to confer selective 
immunization only against a specific pathogen and not toward 
others. Consequently, it would be of great interest to explore new 
vector vaccines based on different viruses. Bovine herpesvirus 4 
(BoHV-4) is a dsDNA genome virus belonging to Herpesviridae 
family, Gammaherpesvirus sub-family and Rhadinovirus genus. 
BoHV-4 natural host is cattle, whereas its best experimental 
host is the rabbit. However, BoHV-4 has been isolated from 
domestic and non-domestic bovine species such as African 
buffalo (Syncerus caffer) (7), American bison (Bison bison), or 
zebus (Bos indicus) and small ruminants such as sheep and goats 
(8). Some feline isolates from lions (9) and cats (10) were also 
reported. Moreover, BoHV-4 isolates were also obtained from 
the kidney of an apparently healthy monkey (Aotus trivirgatus) 
(11). BoHV-4 can replicate in vitro in primary cultures and cell 
lines from a variety of animal species (12–18), whereas in vivo, 
it can experimentally infect mice (16, 19, 20), rats (21), rabbits 
(15), sheep (13), swine (22), and goats (18). Moreover, ex vivo 
non-human primate tissue explants infections have also been 
observed (paper in preparation). Another BoHV-4 important 
feature, which makes it an attractive gene delivery vector, is that in 
contrast to other gamma herpesviruses, BoHV-4 is not oncogenic 
and its infection is not directly linked to a specific pathology. 
Since BoHV-4-based vector has been successfully employed to 
immunize mice (16, 19, 20), sheep (13), and goats (18), in the 
present work, an exploratory immunization study for PPRV in 
mice, before applying BoHV-4-based vector in sheep and goats, 
was performed. A recombinant BoHV-4 expressing the PPRV 
Hemagglutinin gene (Nigeria 75/1 strain) was generated. BoHV-
4-A-PPRV-H-ΔTK immunized mice developed both PPRV 
neutralizing antibodies and PPRV specific T-cell responses. These 
data indicate that this BoHV-4-based vector could be an effective 
PPR vaccine candidate for small ruminants that could distinguish 
between infected and vaccinated animals.
MaTerials anD MeThODs
cells and Viruses
In this study, HEK (Human Embryo Kidney) 293  T (ATCC: 
CRL-11268), BEK (Bovine Embryo Kidney) from Dr. M.Ferrari, 
Istituto Zooprofilattico Sperimentale, Brescia, Italy (BS CL-94), 
and BEK cre, expressing cre recombinase (14), were cultured in 
Eagle’s Minimal Essential Medium (EMEM, Gibco) containing 
10% fetal bovine serum (FBS), 2 mM of L-glutamine (Gibco), 
100 IU/ml of penicillin (Gibco), 100  µg/ml of streptomycin 
(SIGMA), and 0.25 µg/ml of amphotericin B (Gibco) and were 
incubated at 37°C, 5% CO2 in a humidified incubator. Vero Dog-
SLAM (VDS) and RMA-s cell lines (23), kindly provided by Dr. 
Parida (IAH, Pirbright, UK) and Dr McArdle (The Nottingham 
Trent University, UK), respectively, were cultured as described 
in Ref. (24, 25).
constructs generation
Synthetic PPRV-H ORF was first amplified from pGEM-T Easy-
PPRV-H template by PCR using NheI-PPRV-H sense (5′-ccc-
cgctagcccaccatgtccgcacaaagggaaagg-3′) and Phos-PPRV-H 
antisense (5′-agactggattacatgttacctc-3′) pair of primers in order 
to insert NheI restriction site at 5′ terminus and a phosphate 
group at 3′ terminus. The PPRV-H amplicon generated was then 
cloned into NheI/SalI blunt cut pIgK-E2BVDV3-gD106 intermedi-
ate shuttle vector (Clontech) to generate pIgK-PPRV-H-gD106. 
The gD106 tagged fragment was excised from the intermediate 
plasmid cutting with NheI and BamHI blunt restriction enzymes 
to be subsequently cloned inside the pINT2-EGFP final shuttle 
vector cut with NheI and SmaI restriction enzymes in order to 
generate pINT2-PPRV-H-gD106.
Transient Transfection
HEK 293 T cells were seeded into six well plates (3 × 105 cells/
well) and incubated at 37°C with 5% CO2. When cells were sub-
confluent, the culture medium was removed and the cells were 
transfected with pIgK-PPRV-H-gD106, pINT2-PPRV-H-gD106, and 
pEGFP-C1 using Polyethylenimine (PEI) transfection reagent 
(Polysciences, Inc.). Briefly, 3 µg of DNA were mixed with 7.5 µg 
PEI (1  mg/ml) (ratio 1:2.5 DNA:PEI) in 200  µl of Dulbecco’s 
modified essential medium (DMEM) high glucose (Euroclone) 
without serum. After 15  min at room temperature, 800  µl of 
medium without serum were added, and the transfection solution 
was transferred to the cells (monolayer) and left for 6 h at 37°C 
with 5% CO2, in a humidified incubator. The transfection mixture 
was then replaced with fresh medium EMEM, with 10% FBS, 100 
IU/ml of penicillin, 100 µg/ml of streptomycin, and 0.25 µg/ml 
of amphotericin B, and incubated for 24 h at 37°C with 5% CO2.
Western immunoblotting
Protein cell extracts were obtained from a six-well confluent 
plate of HEK 293 T cells transfected with pIgK-PPRV-H-gD106, 
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pINT2-PPRV-H-gD106, and pEGFP-C1 and from 25-cm2 conflu-
ent flasks of BEK cells infected with BoHV-4-A-PPRV-H-ΔTK 
by adding 100  µl of cell extraction buffer (50  mM Tris–HCl, 
150 mM NaCl, and 1% NP-40; pH 8). To analyze cell extracts, 
a 10% SDS-PAGE gel electrophoresis was used. After protein 
transfer in PVDF membranes by electroblotting, the membranes 
were incubated with primary bovine anti gD106 monoclonal anti-
body (clone 1B8-F11; VRMD, Inc., Pullman, WA, USA) diluted 
1:10,000 and then probed with horseradish peroxidase-labeled 
anti-mouse immunoglobulin (SIGMA), diluted 1:10,000, and 
bands visualized by enhanced chemiluminescence (ECL KIT; 
PIERCE).
Bac recombineering and selection
Recombineering was performed as previously described (26) with 
some modifications. For heat-inducible homolog recombination 
in SW102 Escherichia coli (E. coli), containing the BAC-BoHV-
4-A-TK-KanaGalK-TK genome targeted into the TK locus with 
KanaGalK selector cassette, the PvuI linearized pTK-CMV-
PPRV-H-TK expression cassette was used. After recombineer-
ing, only those colonies that were kanamycin negative and 
chloramphenicol positive were kept and grown overnight in 5 ml 
of LB containing 12.5  mg/ml of chloramphenicol. BAC-DNA 
was purified and analyzed through HindIII restriction enzyme 
digestion. DNA was separated by electrophoresis in a 1% agarose 
gel, stained with ethidium bromide, and visualized through UV 
light. Original detailed protocols for recombineering can also be 
found at the recombineering website (https://redrecombineering.
ncifcrf.gov/).
southern Blotting
To further confirm our results, a Southern Blotting with a probe 
spanning H sequence was performed. DNA from 1% agarose 
gel was capillary transferred to a positively charged nylon mem-
brane (ROCHE) and cross-linked by UV irradiation by standard 
procedures (14). The membrane was pre-hybridized in 50 ml of 
hybridization solution (7% SDS, 0.5 M phosphate, pH 7.2) for 1 h 
at 65°C in a rotating hybridization oven (Techna Instruments).
H probe labeled with digoxigenin was generated by PCR with 
NheI-PPRV-H sense (5′- ccccgctagcccaccatgtccgcacaaagggaaagg 
-3′) and Phos-PPRV-H antisense (5′- agactggattacatgttacctc -3′) 
primers, as previously described (15). The PCR amplification 
reaction was carried out in a final volume of 50 µl, containing 
10  mmol Tris–hydrochloride pH 8.3, 5% Dimethyl Sulfoxide 
(DMSO), 0.2  mmol deoxynucleotide triphosphates, 2.5  mM 
MgSO4, 50 mM KCl, and 0.25 µM of each primer. One hundred 
nanograms of DNA were amplified over 35 cycles, each cycle 
consisting of 1  min of denaturation at 94°C, 1  min of primer 
annealing at 60°C, and 2 mins of chain elongation with 1U of Taq 
DNA polymerase (Fermentas) in addition to 1 µl of Digoxigenin-
11-dUTP, alkali-labile (Roche Life Science) at 72°C.
cell culture electroporation and 
recombinant Virus reconstitution
BEK or BEK cre cells were maintained as a monolayer with com-
plete DMEM growth medium with 10% FBS, 2 mM l-glutamine, 
100 IU/ml penicillin and 100  µg/ml streptomycin. When cells 
were sub-confluent (70–90%) they were split to a fresh culture 
flask (i.e., every 3–5  days) and were incubated at 37°C in a 
humidified atmosphere of 95% air, 5% CO2. BAC-DNA (5  µg) 
was electroporated in 600  µl DMEM without serum (Equibio 
Apparatus, 270  V, 960  mF, 4-mm gap cuvettes) into BEK and 
BEK cre cells from a confluent 25-cm2 flask. Electroporated cells 
were returned to the flask, after 24 h the medium was replaced 
with fresh medium, and cells were split 1:2 when they reached 
confluence at 2 days post-electroporation. Cells were left to grow 
until the appearance of cytopathic effect (CPE).
Viruses and Viral replication
BoHV-4-A-PPRV-H-ΔTK and BoHV-4-A were propagated 
by infecting confluent monolayers of BEK cells at a multiplic-
ity of infection (MOI) of 0.5 tissue culture infectious doses 50 
(TCID50) per cell and maintained in medium with only 2% FBS 
for 2 h. The medium was then removed and replaced with fresh 
EMEM containing 10% FBS. When CPE affected the majority of 
the cell monolayer (~72 h post infection), the virus was prepared 
by freezing and thawing cells three times and pelleting the virions 
through a 30% sucrose cushion, as previously described (27). 
Virus pellets were then resuspended in cold EMEM without FBS. 
TCID50 were determined on BEK cells by limiting dilution.
Viral growth curves
BEK cells were infected with BoHV-4-A and BoHV-4-A-PPRV-
H-ΔTK at a M.O.I. of 0.1 TCID50/cell and incubated at 37°C for 
4 h. Infected cells were washed with serum-free EMEM and then 
overlaid with EMEM containing 10% FBS, 2 mM L-glutamine, 
100 IU/ml penicillin, 100  mg/ml streptomycin, and 2.5  mg/ml 
Amphotericin B. The supernatants of infected cultures were 
harvested after 24, 48, 72, and 96 h, and the amount of infectious 
virus was determined by limiting dilution on BEK cells. Viral titer 
differences between each time point are the averages of triplicate 
measurements ±  standard errors of the mean (p >  0.05 for all 
time points as measured by Student’s t-test).
animals and immunizations
Seven- to eight-week old female C57BL/6 mice (Harlan) animals 
were inoculated and boosted after 21 days intraperitoneally (ip) 
with PBS (group 1; n = 10), with 106 TCID50/ml of BoHV-4-A 
(group 2; n = 10) or with 106 TCID50/ml of BoHV-4-A-PPRV- 
H-ΔTK (group 3; n = 10). Animals were bled at 14, 28, and 36 days 
post first immunization. Five animals per group were sacrificed 
at day 7 post-boost to perform T cell response experiments. All 
animal experiments were performed in a disease-secure isola-
tion facility (BSL3) at the CISA (INIA) in strict accordance with 
the recommendations of the Code for Methods and Welfare 
Considerations in Behavioral Research with Animals (Directive 
867609EC; RD1201/2005).
Flow cytometry intracellular cytokine 
staining assays
Splenocytes from inoculated mice were prepared as previ-
ously described (24). For responses to PPRV, splenocytes were 
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cultured overnight with BEI-inactivated PPRV (Nig’75) (28). 
To assess responses to PPRV-H murine T cell epitopes H5 (H(551-
559) YFYPVRLNF) and H9 (H(427-441) ITSVFGPLIPHLSGM) 
(29), splenocytes were expanded in vitro for 1 week with 10 µg/
ml peptide before measuring IFN-γ responses. For intracellular 
IFN-γ measurements, cells were cultured at 106 cells per well in 
the presence of different stimuli (peptide or PPRV) overnight 
before the addition of 10  µg/ml brefeldin-A (Sigma) for the 
last 5 h of incubation. Phorbol myristyl acetate (20 ng/ml) and 
ionomycin (1 µg/ml) (both from sigma) stimulation was used 
as positive control for IFN-γ production. Vehicle (DMSO)-
stimulated (no peptide) or irrelevant peptides (gp33-41 peptide 
(KAVYNFATC) from lymphocytic choriomeningitis virus) were 
used as negative control. No differences in background IFN-γ 
production was detected between these negative control groups. 
Following stimulation, cells were stained with anti-mouse CD4-
FITC and anti-mouse CD8-PerCP antibodies (BDpharmingen). 
Cells were fixed and permeabilized in PBS containing 4% 
paraformaldehyde and 0.1% saponin (wt/vol). Cells were 
then stained with anti-mouse IFN-γ-PE (BD pharmingen) 
and acquired using a FACSCalibur flow cytometer (Becton 
Dickinson). Gating strategy is described in Ref. (29). Gating 
for positive IFN-γ positive events was set using isotype and 
fluorescence minus one channel controls. Data were analyzed 
with FlowJo software (TreeStar Inc.).
Flow cytometry cytotoxicity assays
Splenocytes from BoHV-4-A-PPRV-H-ΔTK immunized mice 
were expanded with H5 peptide for 1 week in  vitro. These 
stimulated splenocytes were used as effector cells. RMA/s 
target cells were labeled with PKH67 green fluorescent linker 
as described in Ref. (30) and pulsed with relevant peptide. 
Vehicle-pulsed (no peptide) RMA/s cells were used as nega-
tive control. Effector cells and target cells were incubated for 
4 hours at 37°C in 96 U-bottom well plates. Cells were then 
transferred to FACS tubes, dead cells labeled with propidium 
iodide (PI) (2  µg/ml), and samples immediately analyzed 
by flow cytometry. Target cells were gated on bright FL1+ 
cells. Positive maximum cell death controls (target cells in 
PBS  +  0.2% saponin) and spontaneous cell death controls 
were used in all experiments. The percentage of specific target 
cell lysis was calculated following the formula: % specific 
lysis = 100 × (% PI+ target – % spontaneous death)/(% maxi-
mum death − % spontaneous death).
PPrV neutralization assays
Serum samples were inactivated for 30 min at 56°C and tested for 
the presence of neutralizing antibodies as previously described 
(31). Briefly, Nigeria 75/1 PPRV stock was incubated with serial 
dilutions of inactivated sheep serum for 1 hour at RT in triplicate. 
VDS cells at a concentration of 1.5 × 105 cells/ml were added to 
each well and incubated for 7 days, fixed with 2% formaldehyde 
and cells visualized by crystal violet staining. Wells without virus 
served as controls. The plates were monitored for PPRV CPE for 
7 days. The VNT titer was defined as the highest dilution of serum 
that inhibited 50% of the CPE. Sera with VNT titers of 1:10 were 
considered negative.
statistical analysis
Power analysis (32) was used to determine treatment group 
size to assess T  cell responses and PPRV seroneutralization. 
Statistical analysis was performed using Prism 5.0 software 
(Graphpad Software Inc., USA). Mann–Whitney test was used 
to compare IFN-γ production in CD4+  and CD8+  T  cells. 




Based on the assumption that PPRV-H antigen could induce 
a protective immune response, a recombinant BoHV-4, 
BoHV-4-A-PPRV-H-ΔTK, delivering an optimized CMV-
PPRV-HgD106 expression cassette (Figure 1A), was generated 
by heat inducible homologous recombination in SW102 E. 
Coli strain containing pBAC-BoHV-4-A-KanaGalK-ΔTK (14) 
(Figure  1B). The so obtained pBAC-BoHV-4-A-PPRV-H-
ΔTK recombinant viral genome authenticity was first assessed 
by HindIII restriction enzyme analysis and then confirmed 
by Southern Blotting using a PPRV-H specific probe. Clonal 
stability was ascertained by growing the positive clone over 20 
passages. Recombinant BoHV-4-A-PPRV-H-ΔTK infectious 
viral particles were then obtained electroporating BEK or 
BEKcre cells. These last cells allowed the depletion of the BAC/
GFP cassette from the recombinant viral genome, as shown by 
the loss of green plaques (Figure  1C). Furthermore, BoHV-
4-A-PPRV-H-ΔTK showed no replication defects comparing 
with the BoHV-4-A parental strain (Figure 1D) and expressed 
PPRV-H protein (Figure 1E).
BohV-4-a-PPrV-h-ΔTK immunization 
induces T cell response against PPrV
Splenocytes from C57BL/6 mice were extracted 7 days after booster 
immunization and IFN-γ production by T  cells to inactivated 
PPRV Nig’75 strain was measured by flow cytometry (Figure 2). 
CD4+ T cells from BoHV-4-A-PPRV-H-ΔTK immunized mice 
produced IFN-γ in response to inactivated PPRV stimulation 
(Figures  2A,B). No specific IFN-γ production to PPRV was 
detected in CD4+ T cells from PBS- or BoHV-4-A immunized 
mice. Similarly, CD8+  T  cells from BoHV-4-A-PPRV-H-ΔTK 
immunized mice produced IFN-γ in the presence of PPRV, 
whereas CD8+  T  cells from PBS- or BoHV-4-A-immunized 
animals did not. These data indicate that BoHV-4-A-PPRV-H-
ΔTK immunization can elicit CD4+ and CD8+ T cell responses 
to PPRV infection.
BohV-4-a-PPrV-h-ΔTK immunization 
induces responses to PPrV-h T cell 
epitopes
Several murine T cell epitopes from PPRV-H in the H-2b context 
were previously defined (29). In the present work, H5 and H9 
peptides from PPRV-H protein were used to further characterize 
the T cell response against PPRV after BoHV-4-A-PPRV-H-ΔTK 
FigUre 1 | Diagram (not to scale); (a) summarizing the heat-inducible homologous recombination in SW102 containing pBAC-BoHV-4-A-TK-KanaGalK-TK, 
where the Kana/GalK cassette was replaced with the CMV-PPRV-HgD106 expression cassette flanked by bovine herpesvirus 4 (BoHV-4) TK sequences,  
located in pINT2 shuttle plasmid vector. (B) Representative 2-deoxy-galactose resistant colonies tested by HindIII restriction enzyme analysis, agar gel 
electrophoresis, and Southern blotting performed with specific probes for the peste des petits ruminants virus hemagglutinin (PPRV-H) ORF ORFs. The 2,650 bp 
band, corresponding to the un-retargeted pBAC-BoHV-4-A-TK-KanaGalK-TK control, has been replaced by a 3240 bp band in pBAC-BoHV-4-A-CMV-PPRV-H-
ΔTK. (c) Representative phase contrast microscopic images of plaque formed by viable reconstituted recombinant BoHV-4-A-PPRV-H-ΔTK after the 
corresponding bacterial artificial chromosome (BAC) DNA electroporation into bovine embryo kidney (BEK) cells expressing cre recombinase (Magnification, ×10). 
(D) Replication kinetics of BoHV-4-A-PPRV-H-ΔTK growth on BEK cells and compared with the parental BoHV-4-A isolate. The data presented are the 
mean ± standard errors of triplicate measurements (P > 0.05 for all time points as measured by Student’s t-test). (e) Western immunoblotting of cells, infected 
with BoHV-4-A-PPRV-H-ΔTK or the parental BoHV-4-A used as a negative control. The lanes were loaded with different amounts of total protein cell extract  
(5, 10, and 20 µg).
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immunization. Splenocytes from immunized mice were sti-
mulated 1  week in  vitro with H5 and H9 peptides and IFN-γ 
production was assessed by flow cytometry using intracellular 
staining (Figure 3). H5 peptide induced specific IFN-γ produc-
tion in CD8+  T  cells but not in CD4+  T  cells of BoHV-4-A-
PPRV-H-ΔTK-immunized mice (Figures  3A,B). No specific 
H5 peptide-stimulated IFN-γ production was detected in PBS 
or BoHV-4-A immunized mice splenocytes. H9 peptide induced 
specific IFN-γ production both in CD4+  and CD8+ T cells of 
BoHV-4-A-PPRV-H-ΔTK-immunized mice (Figures  3C,D). 
No H9 peptide-stimulated IFN-γ secretion was detected in PBS 
or BoHV-4-A groups. BoHV-4-A-PPRV-H-ΔTK immunization 
therefore elicited both CD4+ and CD8+ T cell responses against 
PPRV-H epitopes.
FigUre 2 | Continued
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FigUre 3 | BoHV-4-A-PPRV-H-ΔTK immunization induces CD4+ and CD8+ T cell responses specific for peste des petits ruminants virus hemagglutinin (PPRV-H) 
epitopes Splenocytes from C57BL/6 mice immunized with PBS, BoHV-4-A (BoHV), or BoHV-4-A-PPRV-H-ΔTK (BoHV-PPRV-H) were stimulated in vitro with H5 or 
H9 peptides from PPRV-H for 1 week. IFN-γ production in CD4+ and CD8+ T cells was measured by flow cytometry using intracellular staining. Representative 
dot-plots for IFN-γ production to H5 peptide in (a) CD4+ and (B) CD8+ T cells in immunized mice are shown. Average ± SD specific IFN-γ production to H5 
peptide in immunized mice groups (n = 5 for PBS and BoHV-4-A; n = 7 for BoHV-4-A-PPRV-H-ΔTK) are plotted. Mann–Whitney test [BoHV-4-A-PPRV-H-ΔTK 
(BoHV-4-A-PPRV-H) vs PBS or BoHV-4-A (BoHV)]; *p < 0.05; **p < 0.01. Representative dot-plots for IFN-γ production to H9 peptide in (c) CD4+ and (D) 
CD8+ T cells in immunized mice are shown. Average ± SD specific IFN-γ production to H9 peptide in immunized mice groups (n = 5 for PBS and  
BoHV-4-A; n = 7 for BoHV-4-A-PPRV-H-ΔTK) are plotted. Mann–Whitney test (BoHV-4-A-PPRV-H-ΔTK vs PBS or BoHV-4-A); ** p < 0.01.
FigUre 2 | Induction of CD4+ and CD8+ T cell responses to peste des petits ruminants virus (PPRV) by BoHV-4-A-PPRV-H-ΔTK recombinant vaccine 
Splenocytes from vaccinated C57BL/6 mice were extracted 7 days after booster vaccination and stimulated with inactivated PPRV Nig’75 strain (BEI-PPRV Nig’75) 
overnight. IFN-γ production in CD4+ and CD8+ T cells was assessed by flow cytometry using intracellular staining. (a) Representative dot-plots for IFN-γ production 
by CD4+ T cells in mice vaccinated with PBS, bovine herpesvirus 4 [BoHV-4 (BoHV)], or BoHV-4-A-PPRV-H-ΔTK (BoHV-PPRV-H) are shown. (B) The average ± SD 
percentage of IFN-γ-producing CD4+ T cells above control in 5 mice per group at 7 days post-booster vaccination are shown. Mann–Whitney test (BoHV-4-A-
PPRV-H-ΔTK vs BoHV-4-A or PBS); *p < 0.05; **p < 0.01. (c) Representative dot-plots for IFN-γ production by CD8+ T cells in mice vaccinated with PBS, 
BoHV-4-A, or BoHV-4-A-PPRV-H-ΔTK are shown. (D) The average ± SD percentage of IFN-γ-producing CD8+ T cells above spontaneous IFN- γ release (control) 
in 5 mice per group at 7 days post-booster vaccination are shown. Mann–Whitney test (BoHV-4-A-PPRV-H-ΔTK vs BoHV-4-A or PBS); *p < 0.05; **p < 0.01.
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BohV-4-a-PPrV-h-ΔTK immunization 
stimulates anti-PPrV cytotoxic  
T lymphocytes (cTl)
Splenocytes from BoHV-4-A-PPRV-H-ΔTK-immunized mice 
were H5 peptide-stimulated for 1 week in  vitro and used as 
effector cells in flow cytometry-based cytotoxicity assays. RMA-s 
cells were used as target cells in these experiments. Splenocytes 
from BoHV-4-A-PPRV-H-ΔTK-immunized mice were capa-
ble of specifically lysing RMA-s cells pulsed with H5 peptide 
(Figures  4A,B). These data indicate that BoHV-4-A-PPRV-H-
ΔTK immunization can promote CTL responses against PPRV 
infection.
BohV-4-a-PPrV-h-ΔTK immunization 
induces a specific neutralizing antibody 
response against PPrV-h
To determine the presence of neutralizing antibodies, sera from 
vaccinated mice obtained at 28  days post first immunization 
TaBle 1 | In vitro analysis of neutralization of Nigeria 75/1 peste des petits 
ruminants virus (PPRV) strain infectivity.
neutralization titera
source of antigenb Mouse no. 0 DPic 28 DPid
PBS 1 to 10 <10 <10
BoHV-4A 1 to 10 <10 <10










aSN titers were determined against Nigeria 75/1 PPRV strain and expressed as 
the reciprocal of the last dilution of serum that neutralized 50% of the virus-specific 
cytopathic effect in flat bottom 96 plates.
bIntraperitoneally inoculations of different antigens (see Materials and Methods).
cAnalyzed sera obtained from uninfected mice.
dAnalyzed sera obtained from infected mice 28 days post first immunization (7 days 
post-boost).
FigUre 4 | BoHV-4-A-PPRV-H-ΔTK vaccination induces cytotoxic T lymphocytes (CTL) specific for peste des petits ruminants virus hemagglutinin (PPRV-H) 
epitopes Splenocytes from BoHV-4-A-PPRV-H-ΔTK (BoHV-4-A-PPRV-H) immunized C57BL/6 mice were stimulated with H5 peptide from PPRV for 1 week in vitro 
and used as effector cells in flow cytometry-based cytotoxicity assays. RMA-s cell were used as target cells. RMA-s cell membrane was fluorescently labeled with 
PKH67 marker, and cells pulsed with peptide or left unpulsed as control. After incubation with effector cells, target cell lysis was evaluated by propidium iodide (PI) 
staining. (a) Target cell death was gated in bright PKH67 + and PI + event as shown. (B) Representative specific cytotoxicity of target cells pulsed with H5 peptide 
when cultured with H5-stimulated splenocytes is shown.
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(7 days post booster inoculation) were assayed in a virus neu-
tralization test. All BoHV-4-A-PPRV-H-ΔTK vaccinated animals 
showed PPRV-specific neutralizing antibodies with neutraliza-
tion titers between 160 and 320 (Table 1).
No neutralization activity was detected in pre-immune sera 
or sera from mice injected with either PBS or BoHV-4-A. These 
results show that in vivo inoculation of recombinant BoHV-4-A 
expressing the PPRV-H protein is able to induce the production 
of PPRV neutralizing antibodies, suggesting that this approach 
has the potential to confer protective immunity to BoHV-4-A-
PPRV-H-ΔTK vaccinated animals.
DiscUssiOn
In developing countries, most of the population is engaged in 
small-scale farming, 80% of these households keep livestock 
mostly constituted by small ruminants, primarily sheep and 
goats. Their productivity is constrained by multiple factors, 
including infectious diseases where PPR represents one of the 
most important ones. Vaccination can reduce animal mortality, 
increase milk and meat production, and positively impact on 
household revenues. As a result, vaccination also contributes to 
poverty alleviation by increasing household benefits and free-
ing income for food, healthcare, or child education. Therefore, 
new effective vaccines that target diseases that hamper farming 
in developing countries will have great social and economic 
benefit (33).
For PPRV eradication campaign, a DIVA vaccine would be 
of great value to facilitate PPRV sero-surveillance programs and 
speed up strategies for disease control and eradication (34). The 
most important drawback when a classical live attenuated vac-
cine is used is the inability to distinguish the immune response 
stimulated by vaccination from the one induced by a natural 
infection. A DIVA vaccine would therefore be a smart solution 
that combines vaccination with sero-surveillance. DIVA vaccine 
can be applied not only with gene-deleted marker vaccines (35) 
but also with sub-unit vaccines (36), heterologous vaccines (37), 
and recombinant vector-based vaccines. With regard to the last 
case and as an alternative viral vector, a BoHV-4-based vector 
platform was employed in the present work to deliver and express 
PPRV-H gene in transduced cells of immunocompetent mice as 
surrogate animal model. Although no murine model for PPRV 
induced disease exists, they represent an invaluable model to 
initially test the immunity induced by new prototype vaccines. 
The direct use of large animals could represent a major waste of 
resources, in terms of maintenance and biosafety containment 
structures, especially in the event of experiment failure. Data pro-
vided by immunized mice not only can be obtained quickly and 
cheaply but also they could represent a predictive and orientative 
tool of the vaccine immunogenicity in the natural host, e.g., goats 
and sheep in the specific case of PPRV (4, 25). PPRV-H protein 
possesses both hemagglutinin and neuraminidase activities and 
has a hydrophobic domain at the N-terminus (amino acid posi-
tion 35–38), which remains within the mature protein acting as a 
signal peptide that anchors the protein into the membrane (38). 
The presence of N-terminal 34 amino acids located inside the 
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membrane characterizes PPRV-H as a type II glycoprotein (38). 
Since PPRV-H protein has been shown to be a good candidate 
antigen (3, 4), a recombinant BoHV-4 delivering an optimized 
PPRV-H expression cassette was constructed in order to test the 
immunogenicity of this BoHV-4-based vector and exploit it as 
a DIVA vaccine platform for PPR vaccination. BoHV-4 has no 
clear direct disease association; however, its pathogenic potential 
cannot be absolutely excluded. This is an important consideration 
since it is to be used as a gene delivery vector. In fact, BoHV-4 has 
been often associated with postpartum metritis in cattle along 
with specific endometotropic (39, 40). The secretion of prosta-
glandin E2 (PGE2) and then stimulation of viral replication by 
PGE2, TNF-α, and lipopolysaccharide (LPS) were suggested as 
a pathogenic model for BoHV-4 and bacterial co-infection in 
endometritic cows (41–43). Therefore, a putative non-pathogenic 
biotype of BoHV-4 (BoHV-4-A) isolated from the milk cell frac-
tion of a healthy cow whose genome was cloned as a bacterial 
artificial chromosome (pBAC-BoHV-4-A) (14) was employed. 
Importantly, BoHV-4-A-based vector behaves like a replicating 
incompetent viral vector in both wild-type and immunocom-
promised mice, showing complete absence of pathogenicity 
(16, 17, 19, 27, 44, 45). PPRV-H ORF was customized under the 
transcriptional control of the CMV promoter and integrated 
into BoHV-4-A genome TK locus. The derived replication-
deficient recombinant vector could transduce mammalian cells 
and expressed PPRV-H protein. This construct could therefore 
potentially elicit immunity to the transgene. Genetic stability of 
viral vectors remains a very important issue, since recombinant 
viral vectors constitute “genetically modified organisms” (GMO). 
In our case, the BoHV-4-A-PPRV-H-ΔTK construct was stable 
through several passages. Relevant planning will however be 
needed before this recombinant vector can legally be licensed for 
employment in the field.
Protective natural immunity to morbilliviruses requires 
both humoral and cellular components of the adaptive immune 
system. Humoral immunity can protect against the prototype 
morbillivirus measles virus re-infection, whereas cellular immu-
nity controls virus clearance and dissemination (46, 47). In the 
present work, mice immunized with BoHV-4-A-PPRV-H-ΔTK 
produced CD4+  and CD8+  T  cell responses against PPRV-H 
epitopes and promoted CTL responses against PPRV. This recom-
binant vector vaccine can therefore potentially stimulate the 
T cell immunity essential for virus clearance. It will be interesting 
in future work to determine whether similarly to recombinant 
adenovirus vaccines (29), BoHV-4-A-PPRV-H-ΔTK immuniza-
tion can trigger memory T cell responses in PPRV natural hosts.
However, the most striking results were related to the produc-
tion of virus neutralizing antibodies (VNAs) against PPRV. It was 
previously shown that a neutralization titer higher than 10 cor-
relates with a long-lasting humoral response and could be con-
sidered as a successful vaccination and protection indicator in the 
field (48, 49). In this pilot study, the lowest VNA titer obtained for 
all vaccinated mice was never below 120. It could thus be specu-
lated that vaccinated BoHV-4-A-PPRV-H-ΔTK animals could be 
protected from virulent PPRV challenge when this protocol will 
be/is applied in the natural host. This is further supported by the 
fact that BoHV-4 has been successfully used in sheep and goats 
(13, 18). BoHV-4-based vector delivering H alone also induced 
neutralization titers higher than those obtained with other viral 
vectors delivering both H and F antigens, which is in line with 
the concept that H glycoprotein of Paramyxovirus is a stronger 
inducer of VNA than the F glycoprotein (50, 51). Despite the 
notion that antibody immune response against PPRV is the main 
factor for an efficient protection, cellular immune response can be 
also important for virus clearance. In some cases, protection has 
been obtained even with undetectable level of VNA titers (52, 53). 
The high VNA titer levels and the induction of cellular immunity 
after BoHV-4-A-PPRV-H-ΔTK immunization indicate that this 
recombinant vector vaccine has the potential to protect from 
virulent viral challenge. The induction of humoral and cellular 
immunity after BoHV-4-A-PPRV-H-ΔTK inoculation indicates 
that this vaccine can trigger PPRV immunity in the natural host 
both in an experimental setting and in the field.
In conclusion, in the present paper, it was demonstrated that 
BoHV-4-A-PPRV-H-ΔTK is able to induce a strong specific 
immune response against PPRV. These findings are paving the 
way for BoHV-4-A-PPRV-H-ΔTK use as a safe, large, potent, 
non-integrative, replicating competent viral vector for PPR vac-
cination and eradication.
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